Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial
10.3760/cma.j.issn.1000-6699.2018.04.015
- VernacularTitle:在基础胰岛素治疗血糖控制不佳的亚洲2型糖尿病患者中评估利司那肽的疗效和安全性:GetGoal-L-C随机试验
- Author:
Huisheng XIAO
1
Author Information
1. 中山大学孙逸仙纪念医院内分泌科
- Keywords:
Diabetes mellitus,type 2;
Therapy;
Glucagon-like peptide 1
- From:
Chinese Journal of Endocrinology and Metabolism
2018;34(4):344-348
- CountryChina
- Language:Chinese
-
Abstract:
Almost all the type 2 diabetic patients require insulin therapy as disease progresses over time. However, there are still a large number of patients who fail to achieve glycemic target with basal insulin therapy. How to optimize glycemic control in these patients is a problem in clinical practice. Glucagon-like peptide 1 (GLP-1)receptor agonist is a new type of anti-hyperglycemic agent with complementary mechanisms of actions to basal insulin,helpful for improved glycemic control in type 2 diabetic patients with basal insulin treatment. Therefore, clinical evidence in Chinese population is valuable for clinical diabetes management in China. This paper is the translation of "Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin:The GetGoal-L-C randomized trial",published on"Diabetes,Obesity&Metabolism" in February 2018[Yang W,Min K,Zhou Z,et al. Diabetes,Obesity&Metabolism,2018,20(2):335-343] with open access, which demonstrated efficacy and safety of lixisenatide in a predominantly Asian population with uncontrolled type 2 diabetes as add-on therapy to basal insulin.
